A5101520669- Multiple Sclerosis Research Studies
- Amyotrophic Lateral Sclerosis Research
- Neurogenetic and Muscular Disorders Research
- Parkinson's Disease Mechanisms and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Peripheral Neuropathies and Disorders
- Botulinum Toxin and Related Neurological Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Stroke Rehabilitation and Recovery
- Family and Disability Support Research
- Hereditary Neurological Disorders
- Tracheal and airway disorders
- Rheumatoid Arthritis Research and Therapies
- Cerebral Palsy and Movement Disorders
- Family Support in Illness
- Polyomavirus and related diseases
- Viral Infections and Immunology Research
- Dermatology and Skin Diseases
- Powdery Mildew Fungal Diseases
- Pain Mechanisms and Treatments
- Neurological disorders and treatments
- Herpesvirus Infections and Treatments
- Palliative Care and End-of-Life Issues
- Autoimmune and Inflammatory Disorders Research
- Restless Legs Syndrome Research
University of Liverpool
2016-2025
Walton Centre
2016-2025
University College London
2007-2024
Monash University
2024
Monash Health
2024
Fundació Clínic per a la Recerca Biomèdica
2024
University of Siena
2024
UCL Biomedical Research Centre
2024
University of Amsterdam
2024
Universitat Oberta de Catalunya
2024
<b>Background: </b> Central pain in multiple sclerosis (MS) is common and often refractory to treatment. <b>Methods: We conducted a single-center, 5-week (1-week run-in, 4-week treatment), randomized, double-blind, placebo-controlled, parallel-group trial 66 patients with MS central states (59 dysesthetic, seven painful spasms) of whole-plant cannabis-based medicine (CBM), containing delta-9-tetrahydrocannabinol:cannabidiol (THC:CBD) delivered via an oromucosal spray, as adjunctive analgesic...
Reaching a saturation point in thematic analysis is important to validity qualitative studies, yet the process of achieving often left ambiguous. The lack information about creates uncertainty timing recruitment closure. This exploratory study was conducted demonstrate rigorous approach reaching through two-stage establishment codebook used for analysis. development involved inductive with six interviews, followed by refinement coding system applying them an additional 33 interviews. These...
In June 1999, the Association of British Neurologists (ABN) first published guidelines for use licensed multiple sclerosis (MS) disease-modifying treatments (at that time β-interferon and glatiramer acetate). The were revised in 2001 have been periodically updated since then. 2002, following negative assessment these by National Institute Health Care Excellence (NICE), MS risk-sharing scheme started, which patients eligible according to ABN provided with treatment funded through UK Service...
To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 or very-late antigen-4) on MRI lesion activity in MS.A randomized, double-blind, placebo-controlled trial 72 patients active relapsing-remitting and secondary progressive MS was performed. Each patient received two IV infusions anti-alpha4 (natalizumab; Antegren) placebo 4 weeks apart followed up for 24 serial clinical assessment.The treated group exhibited significantly fewer new...
The symptom of fatigue has been described in a variety ways but absence single taxonomy may be hindering research into this prevalent symptom.To define the fatigue, as experienced by patients with multiple sclerosis (MS), terms common framework, typical medical history.Qualitative phase followed cross-sectional questionnaire survey.Forty patients, clinically definite MS, underwent semi-structured interviews which were analysed within framework of: experience (with derived themes motor,...
Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), a small pilot study patients with ALS showed significant effect lithium on survival. We aimed to assess whether improves survival ALS.The carbonate (LiCALS) trial is randomised, double-blind, placebo-controlled oral taken daily for 18 months ALS. Patients aged at least years who had according the revised El Escorial criteria, disease duration between 6 36 months, were taking riluzole...
<h3>Objective:</h3> To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA) haplotype DR2 or DR4 (DR2<sup>+</sup> DR4<sup>+</sup>). <h3>Methods:</h3> This multicenter randomized 2-year, double-blind, placebo-controlled study included 612 a diagnosis SPMS an Expanded Disability Status Scale (EDSS) score 3.5–6.5, stratified according to baseline EDSS (3.5–5.0, 5.5–6.5) HLA DR4<sup>+</sup>,...
The Hospital Anxiety and Depression Scale (HADS) is commonly used to assess symptoms of anxiety depression in motor neurone disease (MND). measure has never been specifically validated for use within this population, despite questions raised about the scale's validity. This study seeks analyse construct validity HADS MND by fitting its data Rasch model. scale was administered 298 patients with MND. assessment included model fit, differential item functioning (DIF), unidimensionality, local...
BackgroundNeurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test efficacy these an efficient manner with respect time, cost, patient resource.MethodsWe did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 13 neuroscience centres UK....
Objective: Stigma in amyotrophic lateral sclerosis/motor neurone disease (ALS/MND) may be felt or enacted; stigma covers feeling devalued by the illness, whereas enacted refers to being treated differently because of it. ALS/MND has been shown increase social withdrawal, worsen quality life, and reduce use assistive devices, so we explored prevalence factors influencing stigma. Methods: Participants Trajectories Outcome Neurological Conditions-ALS study completed scales measuring stigma,...
Fatigue is a common and debilitating symptom in multiple sclerosis (MS). Best-practice guidelines suggest that health services should repeatedly assess fatigue persons with MS. Several scales are available but concern has been expressed about their validity. The objective of this study was to examine the reliability validity new scale for MS fatigue, Neurological Index (NFI-MS). Qualitative analysis 40 patient interviews had previously contributed coherent definition potential 52 item set...
To explore constructs relevant to self-efficacy in neurological rehabilitation.Qualitative methods using semi-structured interviews.Specialist rehabilitation unit, Liverpool, UK.Twenty-four patients (12 male) with experience of inpatient rehabilitation, aged 17-59 (mean 38.1) years at onset, diagnoses stroke (n = 8), traumatic brain injury 6) or other monophasic impairment 10).Eleven themes emerged from the data that reflect beliefs: self-reliance and independence were deemed important many...
Background: There has been considerable debate regarding the precise relationships between fatigue in multiple sclerosis (MS) and disease-related factors, such as disability, sleep disturbance, depression, age sex. Existing studies give conflicting information. Objective: To clarify a large cross-sectional study, using rigorously developed measurement tool which was based on clear definition of fatigue. Method: A pack containing Neurological Fatigue Index for MS Summary Scale, Hospital...
<h3>Background</h3> The 21-item Modified Fatigue Impact Scale (MFIS) has been recommended as an outcome measure for use in multiple sclerosis and is commonly used to generate overall score of fatigue. <h3>Objective</h3> To test if the MFIS total valid by application Rasch measurement model. <h3>Method</h3> was sent post patients with clinically definite two centres UK. Data were fitted <h3>Results</h3> Analysis based on 415 records (55% response). scale did not fit model mainly because...
Background: The placebo-controlled phase of the PreCISe study showed that glatiramer acetate delayed onset clinically definite multiple sclerosis (CDMS) in patients with isolated syndrome and brain lesions on MRI. Objective: To compare effects early versus treatment open-label PreCISe. Methods: Patients a suggestive MS unifocal manifestation ≥2 T2-weighted were randomized to receive 20 mg/d (early-treatment, n=198) or placebo (delayed-treatment, n=211) for 36 months until conversion CDMS,...
<h3>Objectives</h3> The use of clinical staging in the fatal neurodegenerative disease amyotrophic lateral sclerosis would have value optimising future therapeutic trials. We aimed to previous trial data determine length time patients spend each four proposed stages, its range and transition patterns subsequent stages. <h3>Methods</h3> Using databases from two multicentre trials, were retrospectively staged through course. At stage we assessed whether then progressed an earlier, consecutive...
Objective: To investigate and compare two ALS staging systems, King's clinical Milano-Torino (MiToS) functional staging, using data from the LiCALS phase III trial (EudraCT 2008-006891-31). Methods: Disease stage was derived retrospectively for each system Functional Rating Scale-Revised subscores standard methods. The methods were then compared timing of stages box plots, correspondence chi-square tests, agreement a linearly weighted kappa coefficient concordance Spearman's rank...
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting in death, usually from respiratory failure, within 2-3 years of symptom onset. Non-invasive ventilation (NIV) treatment that when given to patients failure leads improved survival and quality life. Diaphragm pacing (DP), using the NeuRx/4(®) diaphragm system (DPS)™ (Synapse Biomedical, Oberlin, OH, USA), new technique may offer additional or alternative benefits with ALS who are failure. The Pacing Lateral Sclerosis...